HCW Biologics Reports Q3 2026 Financial Results
HCW Biologics reported Q3 2026 revenues of $55,463, up from $15,606 in Q3 2025, and net loss of $3.2 million compared to $4.6 million in the prior year period. For the nine months ended September 30, 2026, revenues were $6.7 million versus $27,222 in the prior year period, primarily driven by the Trimmune licensing agreement, while net loss improved to $5.0 million from $8.7 million. The company disclosed substantial doubt about its ability to continue as a going concern for at least 12 months without additional...
Read source-backed brief